SRGA · Surgalign Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.75M | - | $20.18M | $20.62M | $20.61M | - | $20.55M | $24.83M | $23.29M | - |
| Cost of Revenue | $6.07M | - | $5.49M | $6.41M | $6.41M | - | $6.81M | $7.23M | $6.24M | - |
| Gross Profit | $10.67M | - | $14.69M | $14.21M | $14.20M | - | $13.73M | $17.61M | $17.05M | - |
| R&D | $2.90M | - | $3.87M | $4.08M | $4.45M | - | $2.90M | $3.18M | $2.88M | - |
| SG&A | $21.13M | - | $23.86M | $24.29M | $25.32M | - | $27.56M | $25.54M | $25.94M | - |
| Total Operating Expenses | $24.45M | - | $23.59M | $27.60M | $23.12M | - | $34.61M | $30.88M | $31.48M | - |
| D&A | $499.0K | - | $500.0K | $600.0K | $562.0K | - | $700.0K | $600.0K | $520.0K | - |
| Operating Income | ($1.14M) | - | ($8.00M) | ($13.39M) | ($8.92M) | - | ($16.94M) | ($13.28M) | ($14.43M) | - |
| Interest Expense | $252.0K | - | $252.0K | $252.0K | $252.0K | - | - | - | - | - |
| Income Tax | $133.0K | - | $38.0K | $92.0K | $162.0K | - | ($1.30M) | $81.0K | $219.0K | - |
| Net Income | $4.14M | - | ($9.83M) | ($5.69M) | $27.0K | - | ($7.91M) | ($16.19M) | ($15.19M) | - |
| EPS - Basic | $0.51 | - | ($1.46) | ($0.86) | $0.00 | - | - | - | - | - |
| EPS - Diluted | ($0.03) | - | ($1.71) | ($0.86) | $0.00 | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $22.43M | $16.30M | $13.85M | $29.34M | $44.68M | $51.29M | $68.36M | $69.26M | $63.76M | $43.96M |
| Accounts Receivable | $12.57M | $16.06M | $18.94M | $20.50M | $20.46M | $19.20M | $20.65M | $30.50M | $29.32M | $27.09M |
| Inventory | $13.53M | $17.71M | $22.74M | $25.33M | $22.98M | $26.20M | $27.44M | $26.47M | $22.85M | $22.84M |
| Accounts Payable | $7.49M | $7.71M | $13.06M | $10.56M | $12.09M | $10.20M | $9.48M | $9.58M | $13.14M | $13.42M |
| Current Assets | $53.43M | $56.71M | $66.65M | $86.80M | $101.31M | $105.67M | $136.08M | $149.65M | $120.94M | $104.18M |
| Total Assets | $67.71M | $70.24M | $88.04M | $105.70M | $121.55M | $123.80M | $156.74M | $169.81M | $144.24M | $122.70M |
| Current Liabilities | $19.98M | $21.15M | $34.69M | $37.25M | $28.35M | $54.04M | $55.24M | $52.80M | $56.02M | $46.82M |
| Long-term Debt | $10.61M | $10.61M | $10.61M | $10.61M | $10.61M | $10.61M | - | - | - | - |
| Total Liabilities | $76.64M | $85.97M | $65.66M | $74.86M | $85.86M | $105.56M | $109.63M | $117.00M | $97.86M | $98.53M |
| Stockholders' Equity | ($18.93M) | ($25.73M) | $12.38M | $20.84M | $25.68M | $8.24M | $47.11M | $52.81M | $46.38M | $24.17M |
| Retained Earnings | ($620.07M) | ($624.22M) | ($585.11M) | ($575.27M) | ($569.59M) | ($569.61M) | ($524.25M) | ($516.34M) | ($500.15M) | ($484.96M) |
Cash Flow
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($9.02M) | - | - | - | ($19.14M) | - | - | - | ($14.53M) | - |
| Investing Cash Flow | $15.67M | - | - | - | ($1.34M) | - | - | - | ($2.48M) | - |
| Financing Cash Flow | ($19.0K) | - | - | - | $13.64M | - | - | - | $36.40M | - |
| CapEx | $1.30M | - | - | - | $1.26M | - | - | - | $2.32M | - |
| Free Cash Flow | ($10.32M) | - | - | - | ($20.40M) | - | - | - | ($16.85M) | - |
Ratios
| Metric | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 63.7% | - | 72.8% | 68.9% | 68.9% | - | 66.8% | 70.9% | 73.2% | - |
| Operating margin | -6.8% | - | -39.6% | -64.9% | -43.3% | - | -82.5% | -53.5% | -62.0% | - |
| EBITDA margin | -3.8% | - | -37.1% | -62.0% | -40.6% | - | -79.1% | -51.0% | -59.7% | - |
| Net margin | 24.7% | - | -48.7% | -27.6% | 0.1% | - | -38.5% | -65.2% | -65.2% | - |
| Free cash flow margin | -61.6% | - | - | - | -99.0% | - | - | - | -72.3% | - |
| FCF / Net income | -2.49 | - | - | - | -755.52 | - | - | - | 1.11 | - |
| R&D / Revenue | 17.3% | - | 19.2% | 19.8% | 21.6% | - | 14.1% | 12.8% | 12.3% | - |
| SG&A / Revenue | 126.1% | - | 118.2% | 117.8% | 122.9% | - | 134.2% | 102.8% | 111.4% | - |
| Effective tax rate | 3.1% | - | - | - | 85.7% | - | - | - | - | - |
| Return on assets | 6.1% | - | -11.2% | -5.4% | 0.0% | - | -5.0% | -9.5% | -10.5% | - |
| Return on equity | -21.9% | - | -79.4% | -27.3% | 0.1% | - | -16.8% | -30.7% | -32.7% | - |
| Return on invested capital | - | - | -27.5% | -33.6% | -12.3% | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.67 | 2.68 | 1.92 | 2.33 | 3.57 | 1.96 | 2.46 | 2.83 | 2.16 | 2.23 |
| Quick ratio | 2.00 | 1.84 | 1.27 | 1.65 | 2.76 | 1.47 | 1.97 | 2.33 | 1.75 | 1.74 |
| Cash ratio | 1.12 | 0.77 | 0.40 | 0.79 | 1.58 | 0.95 | 1.24 | 1.31 | 1.14 | 0.94 |
| Leverage | ||||||||||
| Debt / Equity | -0.56 | -0.41 | 0.86 | 0.51 | 0.41 | 1.29 | - | - | - | - |
| Debt / Assets | 0.16 | 0.15 | 0.12 | 0.10 | 0.09 | 0.09 | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -4.5x | - | -31.7x | -53.1x | -35.4x | - | - | - | - | - |
| Equity multiplier | -3.58 | -2.73 | 7.11 | 5.07 | 4.73 | 15.03 | 3.33 | 3.22 | 3.11 | 5.08 |
| Liabilities / Assets | 1.13 | 1.22 | 0.75 | 0.71 | 0.71 | 0.85 | 0.70 | 0.69 | 0.68 | 0.80 |
| Efficiency | ||||||||||
| Asset turnover | 0.25 | - | 0.23 | 0.20 | 0.17 | - | 0.13 | 0.15 | 0.16 | - |
| Inventory turnover | 0.45 | - | 0.24 | 0.25 | 0.28 | - | 0.25 | 0.27 | 0.27 | - |
| Days sales outstanding | 274d | - | 343d | 363d | 362d | - | 367d | 448d | 460d | - |
| Days inventory outstanding | 813d | - | 1513d | 1442d | 1309d | - | 1471d | 1336d | 1337d | - |
| Days payable outstanding | 450d | - | 869d | 601d | 688d | - | 508d | 484d | 769d | - |
| Cash conversion cycle | 637d | - | 986d | 1204d | 983d | - | 1329d | 1301d | 1028d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -18.7% | - | -1.8% | -17.0% | -11.5% | - | -26.4% | -54.2% | -68.4% | - |
| Revenue CAGR (3y) | -39.0% | - | -35.8% | -37.0% | -33.4% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -24.8% | - | 7.0% | -19.3% | -16.8% | - | -14.3% | -23.9% | -57.8% | - |
| Operating income growth (YoY) | 87.2% | - | 52.8% | -0.9% | 38.2% | - | 36.5% | 43.5% | 18.2% | - |
| Net income growth (YoY) | 15251.9% | - | -24.4% | 64.9% | - | - | - | 58.0% | 15.0% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 49.4% | - | - | - | -21.1% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -73.7% | -60.5% | -44.6% | -65.9% | -57.5% | - | 166.2% | -30.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Geographic
$90.50M totalUS$77.93M · 86.1%
Non Us$12.57M · 13.9%
Peer comparison
Same SIC group: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Comparing SURGALIGN HOLDINGS against the 5 most active filers in the same SIC group.